Oct. 9, 2012 | Vol. 11 No. 198 | Full Issue in PDF Format
View the entire issue.
Eli Lilly’s Alzheimer’s disease candidate solanezumab may offer potential as a treatment for milder forms of the disease, new detailed data reveal, but the company’s prospects are still flimsy, with odds of failure potentially exceeding more than 50 percent, one analyst says.
The FDA reclassified its clinical hold on Repros Therapeutics’ Proellex and will now allow the company to conduct a Phase II trial of low-dose Proellex as a treatment for endometriosis.
AstraZeneca (AZ) has agreed to help shepherd Ardelyx’s NHE3-inhibitor program and primary Phase II compound to commercialization, promising to provide the California startup with as much as $272.5 million if new drugs are developed for certain bowel, kidney and renal disorders.
Hospira is recalling one lot of lactated Ringer’s and 5 percent dextrose injection, USP, 1000 mL after receiving a report of a product unit compromised by a leaky container and a “spore-like” structured particulate.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.